The implementation and side effect management of immune checkpoint inhibitors in gynecologic oncology: a JAGO/NOGGO survey
The results of this survey provide valuable insights into physicians' real-world experiences with irAEs associated with ICI treatment. Dealing with serious immune-related and potentially life-threatening side effects has become a routine aspect of clinical practice. Many physicians, however, express a lack of sufficient familiarity with irAEs and their management. Therefore, it is essential to improve medical education, specialized oncological training, and close interdisciplinary collaboration to improve patient care.
Authors
- Jalid Sehouli (ORCID: https://orcid.org/0000-0002-5963-6623)
- M Riedel (ORCID: https://orcid.org/0000-0002-9524-1514)
- Dario Zocholl (ORCID: https://orcid.org/0000-0002-9218-6919)
- Anna Tatzber
- Harald Herrmann (ORCID: https://orcid.org/0000-0002-9959-1781)
- Chiara Flethe
- Klaus Pietzner (ORCID: https://orcid.org/0000-0003-2056-1668)
- Barbara Schmalfeldt (ORCID: https://orcid.org/0000-0001-8142-2915)
- Thomas Bartl (ORCID: https://orcid.org/0000-0002-1938-1574)
- Albert Rössner
Institutions
- Universität Hamburg (DE)
- Johannes Gutenberg University Mainz (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- TUM Klinikum (DE)
- Humboldt-Universität zu Berlin (DE)
- Comprehensive Cancer Center Vienna (AT)
- Zimmer Biomet (Germany) (DE)
- St. Josefs Hospital (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (DE)
- Technical University of Munich (DE)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-01-29
- DOI
- https://doi.org/10.1186/s12885-025-13432-5
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Technische Universität München